Published in Cell Adh Migr on January 16, 2010
5-demethyltangeretin inhibits human nonsmall cell lung cancer cell growth by inducing G2/M cell cycle arrest and apoptosis. Mol Nutr Food Res (2013) 0.88
Ablating all three retinoblastoma family members in mouse lung leads to neuroendocrine tumor formation. Oncotarget (2016) 0.76
Choline plasmalogens isolated from swine liver inhibit hepatoma cell proliferation associated with caveolin-1/Akt signaling. PLoS One (2013) 0.76
STIP overexpression confers oncogenic potential to human non-small cell lung cancer cells by regulating cell cycle and apoptosis. J Cell Mol Med (2015) 0.76
Combination therapy induces unfolded protein response and cytoskeletal rearrangement leading to mitochondrial apoptosis in prostate cancer. Mol Oncol (2016) 0.75
TOX and ADIPOQ Gene Polymorphisms Are Associated with Antipsychotic-Induced Weight Gain in Han Chinese. Sci Rep (2017) 0.75
TRIM47 overexpression is a poor prognostic factor and contributes to carcinogenesis in non-small cell lung carcinoma. Oncotarget (2017) 0.75
Local injection of lentivirus-delivered livinshRNA suppresses lung adenocarcinoma growth by inducing a G0/G1 phase cell cycle arrest. Int J Clin Exp Pathol (2012) 0.75
Aberrant Promoter Methylation at CpG Cytosines Induce the Upregulation of the E2F5 Gene in Breast Cancer. J Breast Cancer (2016) 0.75
AURKA mRNA expression is an independent predictor of poor prognosis in patients with non-small cell lung cancer. Oncol Lett (2017) 0.75
The hallmarks of cancer. Cell (2000) 113.05
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev (1999) 24.83
Checkpoints: controls that ensure the order of cell cycle events. Science (1989) 21.01
The retinoblastoma protein and cell cycle control. Cell (1995) 20.21
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature (2005) 18.30
ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer (2003) 16.06
Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature (2005) 14.65
Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res (2004) 9.70
Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol (2004) 7.22
High-resolution genomic profiles of human lung cancer. Proc Natl Acad Sci U S A (2005) 6.52
VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med (2004) 6.40
MAD2 haplo-insufficiency causes premature anaphase and chromosome instability in mammalian cells. Nature (2001) 6.36
Mammalian cyclin-dependent kinases. Trends Biochem Sci (2005) 5.54
Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer (2006) 4.99
Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell (1999) 4.94
Deregulated cyclin E induces chromosome instability. Nature (1999) 4.75
Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer (2009) 4.66
53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer. Nat Cell Biol (2002) 4.45
Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science (1988) 4.26
Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov (2009) 4.16
Aurora-A - a guardian of poles. Nat Rev Cancer (2005) 4.11
Polo-like kinases: conservation and divergence in their functions and regulation. Nat Rev Mol Cell Biol (2009) 4.09
Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A (1998) 3.80
RB and cell cycle progression. Oncogene (2006) 3.77
Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res (1996) 3.50
Rae1 is an essential mitotic checkpoint regulator that cooperates with Bub3 to prevent chromosome missegregation. J Cell Biol (2003) 3.40
Aurora-A: the maker and breaker of spindle poles. J Cell Sci (2007) 3.20
Mapping of multiple DNA gains and losses in primary small cell lung carcinomas by comparative genomic hybridization. Cancer Res (1994) 2.31
Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene (1997) 2.25
The chromosomal passenger complex: guiding Aurora-B through mitosis. J Cell Biol (2006) 2.07
Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res (1997) 2.05
Transcription factor E2F-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas. J Pathol (2002) 2.04
Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res (1995) 1.99
Plk4 haploinsufficiency causes mitotic infidelity and carcinogenesis. Nat Genet (2005) 1.97
DP and E2F proteins: coordinating transcription with cell cycle progression. Curr Opin Cell Biol (1994) 1.94
Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res (2005) 1.86
Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Res (2000) 1.81
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer (2006) 1.66
Alterations in cell cycle genes in early stage lung adenocarcinoma identified by expression profiling. Cancer Biol Ther (2003) 1.65
Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas. Proc Natl Acad Sci U S A (2007) 1.61
Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells. Cell Motil Cytoskeleton (2004) 1.59
Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation. Cancer Res (2008) 1.58
The clinical significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer. Ann Oncol (2004) 1.52
Expression profiling of primary non-small cell lung cancer for target identification. Oncogene (2002) 1.51
Mutations in the retinoblastoma-related gene RB2/p130 in lung tumors and suppression of tumor growth in vivo by retrovirus-mediated gene transfer. Cancer Res (2000) 1.45
Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation. Lung Cancer (2006) 1.44
Dynamic localization and functional implications of Aurora-C kinase during male mouse meiosis. Dev Biol (2006) 1.43
Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. Br J Cancer (1996) 1.38
CDK4 is a probable target gene in a novel amplicon at 12q13.3-q14.1 in lung cancer. Genes Chromosomes Cancer (2005) 1.38
Homozygous deletions at chromosome 9p21 and mutation analysis of p16 and p15 in microdissected primary non-small cell lung cancers. Clin Cancer Res (1995) 1.37
Distinct pattern of E2F1 expression in human lung tumours: E2F1 is upregulated in small cell lung carcinoma. Oncogene (2001) 1.32
Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients. Mol Cancer Ther (2006) 1.28
p14ARF activates a Tip60-dependent and p53-independent ATM/ATR/CHK pathway in response to genotoxic stress. Mol Cell Biol (2006) 1.25
Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and II. Lung Cancer (2001) 1.24
Complex engagement of DNA damage response pathways in human cancer and in lung tumor progression. Carcinogenesis (2007) 1.24
Mutations in the p16INK4/MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res (1995) 1.23
Loss of the retinoblastoma protein-related p130 protein in small cell lung carcinoma. Proc Natl Acad Sci U S A (1997) 1.23
DNA repair and cell cycle control genes and the risk of young-onset lung cancer. Cancer Res (2006) 1.21
Downregulation of the KIP family members p27(KIP1) and p57(KIP2) by SKP2 and the role of methylation in p57(KIP2) inactivation in nonsmall cell lung cancer. Int J Cancer (2006) 1.21
E2F1 overexpression correlates with thymidylate synthase and survivin gene expressions and tumor proliferation in non small-cell lung cancer. Clin Cancer Res (2007) 1.17
Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer. Cancer Res (2001) 1.16
E2F-1, Skp2 and cyclin E oncoproteins are upregulated and directly correlated in high-grade neuroendocrine lung tumors. Oncogene (2007) 1.14
Frequent hypermethylation of the 5' CpG island of the mitotic stress checkpoint gene Chfr in colorectal and non-small cell lung cancer. Carcinogenesis (2003) 1.13
Codeletion of p15 and p16 genes in primary non-small cell lung carcinoma. Cancer Res (1995) 1.13
Statistical issues in translational cancer research. Clin Cancer Res (2008) 1.12
Histological type-selective, tumor-predominant expression of a novel CHK1 isoform and infrequent in vivo somatic CHK2 mutation in small cell lung cancer. Cancer Res (2000) 1.11
p18Ink4c collaborates with Men1 to constrain lung stem cell expansion and suppress non-small-cell lung cancers. Cancer Res (2007) 1.10
A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg (1999) 1.10
Expression of targeting protein for xklp2 associated with both malignant transformation of respiratory epithelium and progression of squamous cell lung cancer. Clin Cancer Res (2006) 1.09
Mechanisms of p16INK4A inactivation in non small-cell lung cancers. Oncogene (1998) 1.09
CHK2 kinase expression is down-regulated due to promoter methylation in non-small cell lung cancer. Mol Cancer (2004) 1.08
Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability. Br J Cancer (2005) 1.07
Somatic mutation of the hBUB1 mitotic checkpoint gene in primary lung cancer. Genes Chromosomes Cancer (2000) 1.05
Expression of transforming acidic coiled-coil containing protein 3 is a novel independent prognostic marker in non-small cell lung cancer. Pathol Int (2006) 1.04
Reduced expression of the cell cycle inhibitor p27Kip1 in non-small cell lung carcinoma: a prognostic factor independent of Ras. Cancer Res (1999) 1.02
A risk-stratification model of non-small cell lung cancers using cyclin E, Ki-67, and ras p21: different roles of G1 cyclins in cell proliferation and prognosis. Cancer Res (2001) 1.01
Differential expression of Rb2/p130 and p107 in normal human tissues and in primary lung cancer. Clin Cancer Res (1997) 1.01
Prognostic significance of cyclin E overexpression in resected non-small cell lung cancer. Cancer Res (2000) 1.01
p21 expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung. Clin Cancer Res (1997) 1.00
A novel target gene, SKP2, within the 5p13 amplicon that is frequently detected in small cell lung cancers. Am J Pathol (2002) 1.00
Inactivation of the retinoblastoma susceptibility gene in non-small-cell lung cancer. The Lung Cancer Study Group. Oncogene (1993) 0.99
Clinical significance of p21 expression in non-small-cell lung cancer. J Clin Oncol (2002) 0.99
Protective function of p27(KIP1) against apoptosis in small cell lung cancer cells in unfavorable microenvironments. Am J Pathol (2001) 0.98
Differential expression of the retinoblastoma gene family members pRb/p105, p107, and pRb2/p130 in lung cancer. Clin Cancer Res (1996) 0.98
Active cyclin A-CDK2 complex, a possible critical factor for cell proliferation in human primary lung carcinomas. Am J Pathol (1998) 0.96
Cyclin A is associated with an unfavourable outcome in patients with non-small-cell lung carcinomas. Br J Cancer (1997) 0.96
Loss of heterozygosity at the RB locus correlates with loss of RB protein in primary malignant neuro-endocrine lung carcinomas. Int J Cancer (1994) 0.95
Aberrant methylation of p57KIP2 gene in lung and breast cancers and malignant mesotheliomas. Oncol Rep (2004) 0.95
p27KIP1 in human lung cancers: differential changes in small cell and non-small cell carcinomas. Cancer Res (1998) 0.94
Identification of a novel region of homozygous deletion on chromosome 9p in squamous cell carcinoma of the lung: the location of a putative tumor suppressor gene. Cancer Res (1997) 0.94
High cyclin E and low p27/Kip1 expressions are potentially poor prognostic factors in lung adenocarcinoma patients. Lung Cancer (2001) 0.93
Inactivating mutations targeting the chfr mitotic checkpoint gene in human lung cancer. Cancer Res (2003) 0.93
Intragenic mutations of the p16(INK4), p15(INK4B) and p18 genes in primary non-small-cell lung cancers. Int J Cancer (1996) 0.93
Association of CDKN2A(p16)/CDKN2B(p15) alterations and homozygous chromosome arm 9p deletions in human lung carcinoma. Genes Chromosomes Cancer (1998) 0.92
Polymorphisms of STK15 (Aurora-A) gene and lung cancer risk in Caucasians. Carcinogenesis (2006) 0.91
The small-molecule CDK inhibitor, SNS-032, enhances cellular radiosensitivity in quiescent and hypoxic non-small cell lung cancer cells. Lung Cancer (2009) 0.91
Aberrant methylation of p14(ARF), p15(INK4b) and p16(INK4a) genes and location of the primary site in pulmonary squamous cell carcinoma. Pathol Int (2004) 0.91
Mechanism of retinoblastoma gene inactivation in the spectrum of neuroendocrine lung tumors. Am J Respir Cell Mol Biol (1998) 0.90
The ARF tumor suppressor: structure, functions and status in cancer. Int J Cancer (2010) 1.53
Loss of histone H4K20 trimethylation occurs in preneoplasia and influences prognosis of non-small cell lung cancer. Clin Cancer Res (2008) 1.31
p14ARF activates a Tip60-dependent and p53-independent ATM/ATR/CHK pathway in response to genotoxic stress. Mol Cell Biol (2006) 1.25
Acetylation and phosphorylation of SRSF2 control cell fate decision in response to cisplatin. EMBO J (2010) 1.23
p14ARF induces G2 arrest and apoptosis independently of p53 leading to regression of tumours established in nude mice. Oncogene (2003) 1.20
HIV-1 Tat targets Tip60 to impair the apoptotic cell response to genotoxic stresses. EMBO J (2005) 1.14
Abnormal expression of the pre-mRNA splicing regulators SRSF1, SRSF2, SRPK1 and SRPK2 in non small cell lung carcinoma. PLoS One (2012) 1.09
A transcriptomic analysis of human centromeric and pericentric sequences in normal and tumor cells. Nucleic Acids Res (2009) 1.07
Mdm2 overexpression and p14(ARF) inactivation are two mutually exclusive events in primary human lung tumors. Oncogene (2002) 0.98
p14ARF triggers G2 arrest through ERK-mediated Cdc25C phosphorylation, ubiquitination and proteasomal degradation. Cell Cycle (2006) 0.93
Lung cancer: a modified epigenome. Cell Adh Migr (2010) 0.89
SRSF2 is required for sodium butyrate-mediated p21(WAF1) induction and premature senescence in human lung carcinoma cell lines. Cell Cycle (2011) 0.87
The E-cadherin-beta-catenin complex and its implication in lung cancer progression and prognosis. Future Oncol (2005) 0.87
Activation of a Tip60/E2F1/ERCC1 network in human lung adenocarcinoma cells exposed to cisplatin. Carcinogenesis (2011) 0.86
Telomere maintenance and DNA damage responses during lung carcinogenesis. Clin Cancer Res (2010) 0.84
A new function of the splicing factor SRSF2 in the control of E2F1-mediated cell cycle progression in neuroendocrine lung tumors. Cell Cycle (2013) 0.80
Expression of candidate tumor suppressor gene ING2 is lost in non-small cell lung carcinoma. Lung Cancer (2009) 0.77
RNA splicing, cell signaling, and response to therapies. Curr Opin Oncol (2016) 0.75